INTRODUCTION
As value-based healthcare and quality improvement initiatives become more entrenched in modern medical culture, numerous systems of collecting and describing patient-reported outcome measures (PROMs) have emerged across medical practices and specialties. [1] [2] [3] Although PROMs are a well-known tool to evaluate both patient safety and satisfaction, they can also be used to measure processes of care, health service delivery, and institutional performance. Previous findings using PROMs have in fact shown that outcome measures among surgeons and institutions can be highly variable for procedures such as abdominal aortic aneurysm repair, carotid endarterectomy, cancer surgery, pancreatic resection, and laparoscopic Nissen fundoplication. [4] [5] [6] [7] [8] For endoscopic sinus surgery (ESS) for chronic rhinosinusitis (CRS), a change or improvement in disease-specific quality-of-life (QOL) has been adopted as a primary PROM of interest for this patient population. [9] [10] [11] In support of this guideline, single and multiinstitutional studies using a variety of patient-based outcomes for ESS have been widely published in the last decade. [12] [13] [14] [15] [16] [17] [18] A comparison of ESS outcomes for CRS between institutions and/or surgeons is, however, currently lacking and will be a necessary component of value-based healthcare for the practice of rhinology.
The objective of this investigation was to evaluate ESS outcomes for CRS between several academic medical centers to determine if differences in QOL outcomes could be detected. In addition, we sought to identify factors that might impact outcomes and would need to be considered in the development of an ESS-specific riskadjustment model so that outcomes may be appropriately compared between institutions and healthcare providers.
MATERIALS AND METHODS

Study Population and Inclusion Criteria
Study participants consisted of adult patients ( 18 years of age) referred to tertiary surgeons with a confirmed diagnosis of medically refractory CRS. Diagnostic criteria for CRS consisted of guidelines endorsed by the American Academy of Otolaryngology. 19 Study participants elected to pursue ESS following unsuccessful medical regimens including, but not limited to, at least one course (> 14 days) of culture-directed or broad-spectrum antibiotics, at least one trial of either topical corticosteroids (> 21 days) or a 5-day course of oral corticosteroid therapy, and daily saline irrigations (> 21 days). These treatment criteria were develop based on a consensus of expert opinion of the coauthors prior to enrollment.
Participants provided written, informed consent in English and agreed to complete preoperative and postoperative study evaluations per the study protocol. An academic, institutional review board provided study approval, with continuing annual reviews with each enrollment center. Study participants were prospectively enrolled, observed, and evaluated through the standard of care surrounding ESS for CRS for 6 months postoperatively. Study participation was voluntary and did not alter the standard of care.
Surgical Intervention
Surgical approach was directed by the enrolling clinician and guided by symptomatic, radiographic, and endoscopic indications of disease severity. Endoscopic sinus surgery procedures consisted of maxillary antrostomy; partial or total ethmoidectomy; sphenoidotomy; or frontal sinusotomy procedures, with septoplasty and inferior turbinate reductions as adjunctive procedures as determined necessary by the treating surgeon. All surgical cases were followed with appropriate evidence-based postoperative therapeutic regimens, including daily nasal saline rinsing, topical corticosteroid therapy, and other appropriate medical therapies, as determined necessary by the treating surgeon. 20 
Clinical Measures of Disease Severity
Radiographic and endoscopic diagnostic evaluations of disease severity were collected during preoperative clinical assessments and utilized for study objectives. High-resolution computed tomography (CT) was utilized to evaluate sinonasal disease severity using 1.0-mm contiguous images in both sagittal and coronal planes. Images were staged by each on-site enrolling surgeon in accordance with the Lund-Mackay scoring system. 21 The paranasal sinuses were evaluated bilaterally using rigid, fiberoptic 0-degree to 30-degree endoscopes by each onsite enrolling physician. Endoscopic exams were staged in accordance with the Lund-Kennedy scoring system. 22 Endoscopy scores were also collected during 6-month clinical followup.
Disease-Specific, Patient-Reported Outcome Measures
The primary PROM of interest to this investigation was the 22-item SinoNasal Outcome Test (SNOT-22; Washington University, St. Louis, MO), a validated instrument developed to quantify symptom severity associated with sinonasal conditions. 23, 24 Individual item scores are measured using patientselected Likert scale responses for which higher scores indicate worse symptom severity as follows: 0 5 no problem; 1 5 very mild problem; 2 5 mild or slight problem; 3 5 moderate problem; 4 5 severe problem; 5 5 problem as bad as it can be. Higher total scores on the SNOT-22 suggest worse patient functioning or symptom severity (total score range: 0-110). The 22-items of the SNOT-22 survey have previously been categorized and summarized into five distinct domains: rhinologic symptoms (score range: 0-30), extra-nasal rhinologic symptoms (score range: 0-15), ear/facial symptoms (score range: 0-25), psychological dysfunction (score range: 0-35), and sleep dysfunction (score range: 0-25),as previously described. 25 The minimal clinically important difference (MCID) for SNOT-22 total scores has been previously described as a within-subjects improvement of at least 8.9 points. 23 The secondary outcome of interest was the Rhinosinusitis Disability Index (RSDI), a 30-item survey instrument developed to quantify symptom severity associated with CRS in a complimentary fashion. The RSDI consists of three domains that evaluate the impact of CRS on a respondent's physical (range: 0-44), functional (range: 0-36), and emotional (range: 0-40) domains. Individual item scores are measured using patientselected Likert scale responses for which higher scores indicate worse symptom severity: 0 5 never, 1 5 almost never, 2 5 sometimes, 3 5 almost always, and 4 5 always. Higher total scores on the RSDI suggest worse patient functioning or symptom severity (total score range: 0-120). 26 The MCID for RSDI total scores have previously been defined as a withinsubjects improvement of at least one-half standard deviation (SD) of the preoperative mean score.
14,27 Each on-site enrolling surgeon was blinded to survey responses for the entire study duration.
Medication Use Measures
Participants were asked to provide additional information regarding perioperative medication use for treatment of CRS specifically. At both preoperative and 6-month postoperative evaluations, patients recalled the number of days (out of the previous 90 days) that they utilized medications for the treatment of their sinus disease, including topical nasal steroid sprays, topical nasal steroid drops/irrigations, decongestants, oral/systemic antibiotics, oral/systemic corticosteroids, antihistamines, leukotriene modifiers, and saline irrigation rinses.
Study Exclusion Criteria
Study participants were excluded from final analyses if they did not complete all preoperative enrollment procedures and evaluations or had not yet completed the 6-month postoperative follow-up time period.
Data Management and Statistical Analysis
Protected health information was removed, and study data was safeguarded using unique study identification (ID) number assignments for each participant. Study data was securely transferred to Oregon Health and Science University, Portland, Oregon, from each enrollment site for manual entry into a passwordprotected relational database (Access; Microsoft Corp, Redmond, WA). All statistical analyses were completed using commercially available software (SPSS v.22; IBM Corp., Armonk, NY). In order to avoid enrollment bias by treating surgeons, blinding of all study data to provider/institution was performed and maintained throughout the entire project, including all coauthors. All unique study ID numbers were removed, and each patient entry received alternative random number assignment. In order to blind all investigators and statisticians, each institution was reassigned a unique site ID designation by personnel not associated with this investigation. The site with the lowest number of participants with appropriate follow-up yielded a sample of n 5 76. Therefore, n 5 76 subjects were then randomly chosen from each of the other sites for final analysis.
Data was evaluated descriptively, whereas normality or skewness was verified for all ordinal or continuous measures. Patient characteristics, comorbid status, and surgical procedures were all compared for omnibus differences across enrollment sites using either one-way analysis of variance (ANOVA; F-test), Kruskall-Wallis, or Chi-square testing, with two-sided bivariate multiple comparison testing where appropriate. Further ANOVA testing was used to compare differences in mean preoperative and postoperative QOL scores between enrollment sites. Two-sided matched pairs t testing was utilized to identify significant within-subjects improvement in QOL across each enrollment site. Test statistics were provided for all normally distributed data where appropriate.
Simple stepwise linear regression was used to identify significant independent risk factors associated with 6-month postoperative mean improvement (postoperative scores minus preoperative scores) for SNOT-22 and RSDI total scores, when appropriate. Preliminary models included enrollment site as the main exposure variable of interest and all other independent factors screened for univariate significance (P < 0.250). A total of 25 variables were additionally screened for univariate, independent significance, including preoperative patient characteristics, preoperative QOL status, and 6-month postoperative medication use cofactors. Final models used a manual forward selection (P < 0.100) and backward elimination (P < 0.050) process, and multicollinearity was evaluated using variance inflation factors (VIFs). Significant covariates were introduced into final models to assess potential confounding of the effect estimate for enrollment site difference. Any covariate resulting in an absolute change of 610% in the effect estimate value for the site variable was considered a confounder. 28, 29 Unadjusted and adjusted regression coefficients (b), standard errors (SE), 95% confidence intervals, and estimates of type-I error (P values) are reported. The percentage of final model variance explained by each model was calculated using coefficients of multiple determination (R 2 ).
RESULTS
Final Cohort Characteristics
Final analysis was conducted on a cohort of 228 study participants (76 patients from each site) with CRS who met inclusion criteria, completed all preoperative study requirements, and underwent ESS between April 2011 and May 2015. Final cohort characteristics and preoperative clinical measures of disease severity are delineated across enrollment sites in Table I . Important baseline factors were similar among the sites: age, gender, prior sinus surgery, polyposis, aspirin sensitivity, allergy, depression, and tobacco abuse. The prevalence of both septal deviation and oral corticosteroid-dependent conditions was significantly different between enrollment sites (both P < 0.004). Clinical measures of disease severity (CT and endoscopy scores) were also found to be significantly different between enrollment sites (P 0.006) ( Table I) .
Baseline Quality of Life, Medication Use, and Surgical Procedures Performed Between Sites
Average preoperative scores for each diseasespecific QOL outcome measure were compared between enrollment sites (Table II) . Average, preoperative QOL status was comparable between all sites, with the exception of worse sleep dysfunction domain scores, as measured by the SNOT-22 survey (P 5 0.009). Mean preoperative days of medication usage for sinus disease were additionally compared between enrollment sites (Table III) . Study participants used similar durations of preoperative medications across enrollment sites, with the exception of variations in exposure to decongestants (P 5 0.004) and saline irrigation rinses (P 5 0.021).
The frequencies of surgical procedures between enrollment sites are described in Table IV and are similar, with the exception of septoplasty, which was performed significantly more commonly at enrollment sites no. 2 and no. 3 relative to enrollment site no. 1.
Postoperative Improvements in Quality of Life Between Sites
Unadjusted, mean improvement in each QOL measure was evaluated between all three enrollment sites to compare magnitudes of 6-month postoperative improvement (Table V) . All enrollment sites reported significant postoperative improvement 6 months after ESS across QOL measures (P < 0.001). The magnitude of mean improvement was found to be significantly different between enrollment sites for some QOL outcomes, including the primary outcome SNOT 22 (220.5 vs. 226.8 vs. 229.1; P 5 0.027).
Comparison of Postoperative Medication Use Between Sites
Average days of postoperative medication use (out of the previous 90) for treatment of sinus disease were also compared between enrollment sites in a similar fashion (Table VI ). Significant differences were found in topical steroid use (sprays, drops/irrigations) postoperatively, suggesting that enrollment site no. 1 either prescribed these less frequently, or patients enrolled at that site were less compliant with prescribed therapy.
Linear Regression Modeling
The final unadjusted and adjusted stepwise linear regression model for cofactors independently associated with improvement in total SNOT-22 scores are described in Table VII . Objective disease severity, as measured by CT and endoscopy, varied across sites, but these factors did not impact outcomes and did not require adjustment. The effect estimates on SNOT-22 change scores for baseline QOL, septoplasty, postoperative medication use, and oral corticosteroid-dependent condition are described in the order of increasing magnitude. After adjusting for all independent cofactors, enrollment site was no longer a significant variable associated with 6-month postoperative improvement in SNOT-22 scores (P 5 0.535). Final independent model cofactors were able to explain 41% of overall model variance, whereas no evidence of multicollinearity between variables was found (VIFs < 2.0).
DISCUSSION
These data show that clinically meaningful improvements in QOL following ESS for CRS occurred in all three centers that we evaluated. However, without adjustment for multiple cofactors, there was a statistically significant difference in improvement between the three enrollment centers, with a 20 point improvement in SNOT-22 total scores on the low end and a 30 point improvement on the higher end on average. Although the baseline characteristics of patients treated at each of the centers were relatively similar, important predictors of improvement were identified, including baseline SNOT-22 total scores and the prevalence of oral steroiddependent comorbidity. Due to the fact that the effect estimate for the main exposure variable was confounded by other cofactor differences, inclusion of baseline/preoperative QOL scores was warranted and improved overall model efficiency. 30 In addition, important and significant differences in unadjusted, average SNOT-22 total score improvements were found between enrollment sites for patients with baseline septal deviation and the subsequent performance of concurrent septoplasty.
In final regression models, mean differences in outcomes between enrollment sites became nonsignificant after accounting for differences in baseline QOL, oral steroid-dependent diseases, and performance of concurrent septoplasty. In addition to comparing postoperative differences in mean SNOT-22 improvement scores, the unadjusted prevalence of participants achieving at least one MCID in disease-specific QOL scores was different between enrollment sites. A significantly lower prevalence (P 5 0.013) of improvement was reported for enrollment site no. 1 for SNOT-22 total scores compared to enrollment sites no. 2 and no. 3 (68% vs. 87% and 83%, respectively). These data demonstrate proof of concept that differences in QOL outcomes of ESS for CRS can be detected between centers using a variety of analytical approaches, and important factors must be considered when interpreting such a comparison, including clinical and treatment differences between the sites.
Baseline characteristics that have been previously implicated in potentially reducing improvement in PROMs following ESS include prior ESS, acetylsalicyclic acid intolerance, depression, psychological distress/anxiety, and tobacco abuse.
14,31-36 All of these factors were evaluated as part of this investigation but were found to occur at similar prevalence between enrollment sites. In future studies that include nontertiary sites, where some of these factors will likely occur with differing frequencies, these potential predictive factors will need to be carefully considered in any comparison of outcomesand adjusted for if necessary.
We did not anticipate a difference in the rate of septal deviation or the performance of concurrent septoplasty between the sites. Even more surprising was the apparent impact of septoplasty on outcomes (Table VIII) . Some studies have suggested that concurrent septoplasty does not associate with treatment outcomes of ESS. 37 It is clear to all who perform this surgery that the decision to perform concurrent septoplasty is based on several factors, including extent of deviation, potential impact on access to the sinuses for ESS and postoperative debridement, postoperative drug delivery, and baseline patient-specific symptoms such as nasal airway obstruction. It is unclear whether performance of septoplasty was based on fundamental differences in surgical philosophy or differences in the prevalence of deviation across centers, but none of the other surgical procedures differed among the centers, including procedures that were considered more advanced. It is also interesting that differences in total SNOT-22 outcomes were driven by differences in the ear/facial and psychological domains of the instrument. Although it would seem logical that septoplasty would improve nasal obstruction, and therefore the rhinologic domain, the impact of septoplasty may be more all-encompassing if it improves drug delivery postoperatively. The reasons why septal deviation impacts outcomes and indications for performing septoplasty are still unclear, and this topic deserves further study.
The magnitude of association of oral steroiddependent diseases with reduced SNOT-22 total score improvement deserves further discussion. It is apparent to sinus surgeons that oral steroid-dependent sinusitis or asthma would be indicative of a particularly severe form of inflammation that might impact disease-specific outcomes, and 16 of 22 steroid-dependent patients collectively fell into this category. Unfortunately, the classification of steroid dependence and the requirement for patients to be on chronic steroids for any condition can be arbitrary depending on varying clinician practices. Chronic steroid use will also potentially impact baseline QOL, endoscopy, and CT scores-and could potentially modify reported effect estimates. Interestingly, six of 22 steroid-dependent patients suffered autoimmune diseases. These data suggest that patients with autoimmune diseases who are oral steroid-dependent experience less improvement with sinus surgery. Future studies with strict criteria for inclusion of steroiddependent subjects are another area for future research.
Limitations of our study include the inclusion of sites with only fellowship-trained, tertiary surgeons, which limits the variability in baseline patient factors and the generalizability of these findings. However, this comparison is novel, quite challenging to perform, and a necessary step in today's healthcare environment. Another limitation is the recall-based medication use measures, which are subject to recall bias. Despite this, critical preoperative medication use for the treatment of CRS, such as antibiotic and steroid therapy, appeared similar at all three sites. On the other hand, postoperative use of topical steroids (e.g., sprays, drops, irrigations) was utilized by patients significantly less at enrollment site no. 1, suggesting that either surgeons prescribed these less frequently or that patient compliance with these medications was reduced at that site. Analysis demonstrated that less postoperative topical steroid was significantly associated with less improvement in SNOT-22 but was clinically irrelevant (i.e., trivial effect size).
Throughout this investigation, the identification of enrollment sites was blinded for all authors and contributors as a condition of entering the study. This was accomplished in order to avoid patient selection bias that might occur if surgeons knew the data would become public. Our objective was not to report outcomes for specific institutions or surgeons but rather to demonstrate that such a comparison is possible, and to begin an analysis of confounding factors for which we must account in such comparisons. The future of clinical research consortiums will likely be impacted by the reporting of these data, and we have treated these data with considerable sensitivity.
CONCLUSION
Comparison of surgeon outcomes of ESS is feasible and must take into account a number of different baseline characteristics, including baseline QOL, septal deviation, and steroid-dependent illnesses. Further studies using a variety of sites will be critical to enhancing baseline variability of important patient factors (e.g., history of prior surgery, aspirin intolerance, depression/psychosocial distress) toward developing an ESS-specific riskadjustment model and enabling a robust comparison of surgeon outcomes. 
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